Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-12-03 3:20 pm Purchase | 2025-11-25 | 13G | VERRICA PHARMACEUTICALS INC CO VRCA | Affinity Asset Advisors, LLC | 884,172 5.470% | 884,172 (New Position) | Filing History |
| 2025-12-03 3:19 pm Sale | 2025-08-19 | 13G | IBIO INC PAR $0.001 IBIO | Affinity Asset Advisors, LLC | 2,181,420 9.990% | -2,098,580 (-49.03%) | Filing History |
| 2025-11-14 4:10 pm Sale | 2025-09-30 | 13G | NEXTCURE INC NXTC | Affinity Asset Advisors, LLC | 191,882 7.170% | -1 (-0.00%) | Filing History |
| 2025-11-13 5:21 pm Purchase | 2025-09-30 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Affinity Asset Advisors, LLC | 1,006,217 7.650% | 455,452 (+82.69%) | Filing History |
| 2025-10-23 4:07 pm Purchase | 2025-10-16 | 13G | SUTRO BIOPHARMA INC STRO | Affinity Asset Advisors, LLC | 658,377 7.770% | 658,377 (New Position) | Filing History |
| 2025-08-26 4:47 pm Purchase | 2025-08-19 | 13G | IBIO INC PAR $0.001 IBIO | Affinity Asset Advisors, LLC | 4,280,000 9.990% | 4,280,000 (New Position) | Filing History |
| 2025-06-04 4:04 pm Purchase | 2025-05-28 | 13G | LEXEO THERAPEUTICS INC LXEO | Affinity Asset Advisors, LLC | 4,252,005 7.750% | 4,252,005 (New Position) | Filing History |
| 2025-05-30 7:01 pm Purchase | 2025-05-22 | 13G | VENTYX BIOSCIENCES INC VTYX | Affinity Asset Advisors, LLC | 4,057,105 5.700% | 4,057,105 (New Position) | Filing History |
| 2025-05-30 5:24 pm Sale | 2025-05-20 | 13G | INOZYME PHARMA INC INZY | Affinity Asset Advisors, LLC | 1,867,710 2.890% | -2,104,608 (-52.98%) | Filing History |
| 2025-04-10 5:23 pm Purchase | 2025-04-03 | 13G | KARYOPHARM THERAPEUTICS INC CO KPTI | Affinity Asset Advisors, LLC | 664,224 7.830% | 664,224 (New Position) | Filing History |
| 2024-12-31 4:13 pm Purchase | 2024-12-23 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Affinity Asset Advisors, LLC | 550,765 5.300% | 550,765 (New Position) | Filing History |
| 2024-12-09 4:14 pm Purchase | 2024-12-02 | 13G | INOZYME PHARMA INC INZY | Affinity Asset Advisors, LLC | 3,972,318 6.180% | 3,972,318 (New Position) | Filing History |
| 2024-11-13 4:06 pm Purchase | 2024-09-30 | 13G | NEXTCURE INC NXTC | Affinity Asset Advisors, LLC | 191,883 8.220% | 52,480 (+37.65%) | Filing History |
| 2024-08-14 4:05 pm Purchase | 2024-06-30 | 13G | CLIMB BIO, INC. CLYM | Affinity Asset Advisors, LLC | 1,813,193 2.700% | 143,193 (+8.57%) | Filing History |
| 2024-06-27 4:47 pm Purchase | 2024-06-20 | 13G | NEXTCURE INC NXTC | Affinity Asset Advisors, LLC | 139,403 5.980% | 139,403 (New Position) | Filing History |
| 2024-05-07 6:01 pm Purchase | 2024-05-01 | 13G | CLIMB BIO, INC. CLYM | Affinity Asset Advisors, LLC | 1,670,000 6.020% | 1,670,000 (New Position) | Filing History |
| 2024-02-13 4:55 pm Sale | 2023-12-31 | 13G | VINCERX PHARMA, INC VINC | Affinity Asset Advisors, LLC | 0 0.000% | -74,639 (Position Closed) | Filing History |
| 2024-02-13 4:48 pm Purchase | 2023-12-31 | 13G | SPYRE THERAPEUTICS, INC SYRE | Affinity Asset Advisors, LLC | 653,409 1.810% | 354,329 (+118.47%) | Filing History |
| 2024-02-13 4:45 pm Sale | 2023-12-31 | 13G | CONTEXT THERAPEUTICS INC CNTX | Affinity Asset Advisors, LLC | 328,817 2.060% | -554,837 (-62.79%) | Filing History |
| 2023-07-03 4:20 pm Purchase | 2023-06-22 | 13G | AEGLEA BIOTHERAPEUTICS, INC. C AGLE | Affinity Asset Advisors, LLC | 299,080 9.230% | 299,080 (New Position) | Filing History |